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Introduction    
    When treating multiple complex diseases such as cancer, polytherapy may demonstrate 
efficiency than monotherapy. However, due to the multiplicative relationship between the 
number of drugs and cell lines versus the number of combinations, it is impractical to test all 
drug combinations using high-throughput preclinical approaches. An alternative to 
experimental tests is predicting drug synergy through computational models. Here, we 
summarize recent computational approaches for predicting drug synergy, discuss current 
limitations, and propose future directions. 
Background 
Polytherapy, the combination of two or more drugs, often achieves better clinical outcomes 
than monotherapy through reducing drug toxicity and improving therapeutic efficacy. The 
degree to which multiple drugs synergize or antagonize is quantified by the drug synergy score. 
Traditionally, the synergy score is measured through in vitro or in vivo drug screening 
experiments and calculated by comparing it with the additive effect of individual drug 
treatments. However, since the number of drug combinations grows exponentially with the 
number of drugs, it is infeasible to experimentally test the synergistic effects of all possible 
drug combinations in multiple cell lines under consideration. Recently, there is a growing trend 
in leveraging computational techniques to extract relevant biological signals from available 
drug combination datasets, build predictive machine learning models, and provide guidance 
for experimental design across diverse diseases and studies.  
    Artificial Intelligence (AI) is a field of computer science that aims to bring human-like 
intelligence to the world of computing. Machine Learning (ML) can be recognized as a type of 
AI, which aims to let machine to learn and extract signals from data. There are two major types 
















training data with desired supervisory labels and predicts labels for new data, and (ii) 
unsupervised learning that infers characteristic patterns from data without predefined labels. 
For supervised learning, the predictive performance is evaluated by comparing predicted labels 
with experimentally measured labels on the held-out testing data, using scoring metrics such 
as Pearson’s correlation coefficient. Currently, ML algorithms have been successfully applied 
to solve various biological and biomedical problems. In this paper, we will first introduce 
several ML approaches for predicting drug combination synergy.  
Current Methods 
    In the AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge, a large 
dataset1 was used to systematically evaluate the predictive performance of computational 
models. The winning algorithm introduced a novel network propagation method to simulate 
the post-treatment genomic profile from the pre-treatment profile of a cancer cell line based on 
drug target information and the gene-gene interaction network2. Together with the simulated 
genomic profiles, the monotherapy data were used to build tree-based conventional ML models 
for predicting drug synergy (Figure 1A). When tested on a sizeable held-out dataset, this 
method ranked first among 160 teams in the challenge and established a new state-of-the-field 
algorithm in the pharmacogenomics research community. Of note, this method is approaching 
the accuracy of experimental replicates and potentially guide experimental design for future 
candidate drug pairs.  
Recently, a new class of ML algorithm, Deep Learning (DL), has shown great promise to 
address many biomedical problems. DL utilizes multiple, or “deep”, nonlinear layers to 
progressively extract high-level features from the input. DeepSynergy is an example of how 
DL can be used for predicting drug combination synergy3 (Figure 1B). DeepSynergy accepts 
















inputs - the latter input was not provided in the previous DREAM challenge. This model was 
trained on the O’Neil’s dataset4 and surpassed other traditional machine learning algorithms.  
Furthermore, Regan-Fendt et al. presented SynGeNet5, an innovative network that predicts 
drug combination effects by integrating transcriptomics-based connectivity mapping and 
network centrality analysis with clustering algorithms. They demonstrated that SynGeNet 
outperformed several other tools that used disease- and drug-associated gene expression data 
to predict drug combination synergy (Figure 1C). 
Besides, Cheng et al. proposed a network-based approach to identify drug combinations6 
(Figure 1D). They used the bootstrapping algorithm, z-score and separation measurement to 
analyze the distance between drug targets and disease proteins. They demonstrated that the 
network-based approach outperformed traditional approaches, and the network proximity 
offered an effective strategy to identify new drug combinations. 
Limitations 
Although pioneering efforts have been made to develop ML models for predicting drug 
combination synergy as we mentioned above, there are still some limitations. 
Firstly, owing to the lack of sufficient data size, current models may not have a comparable 
prediction when applied to external datasets. This is because most public datasets contain a 
relatively small portion of all possible drug combinations. When trained on a small dataset, ML 
models may overfit to the training data, resulting in higher errors during testing. Menden et al.1 
also reported that when applying the top-performing models in the DREAM challenge to the 
O’Neil’s dataset4, the results became worse than those on their original dataset. This is 
especially true when two datasets only have few common drugs or cancer cell lines. The cohort 
and batch effects further introduce noise and differences among datasets. Therefore, a model 
















    Secondly, it is also vital to improve the biological interpretation of ML models. Hidden prior 
knowledge is often crucial for developing a powerful prediction model and a better 
understanding of the mechanism underlying drug synergism. For instance, Li et al.2 leveraged 
prior information of the gene-gene interaction network and drug target genes to improve 
prediction accuracy, and in DeepSynergy3, both genomic profiles and chemical compounds were 
considered. However, it remains unknown to what extent the hidden biological information is 
needed to perfectly predict drug synergy. Gilvary et al.7 mentioned that AI approaches made 
significant contributions to several research fields in medicine, but predictive performance can 
be further improved by developments of biological understanding. In recent years, a surging 
number of papers was published, which aimed to improve the representation of hidden 
biological information. For instance, Wang et al.8 proposed a gene set embedding method, 
GRep, to learn the representation of biological information. They described that the GRep 
framework could also be applied to other biological analyses like drug networks. If we can 
exploit hidden biological information and integrate it into ML models, we will achieve better 
predictive performance in the future. 
    Lastly, different evaluation metrics have been used in different studies. Without a common 
evaluation metric, it is difficult to compare different models objectively. Data science 
challenges such as DREAM are examples of unbiasedly comparing computational methods 
using the same scoring metric on the same held-out testing datasets. We recommend that a set 
of standard and official evaluation metrics should be used for the research community.  
Future Directions 
Despite those limitations discussed in the previous section, the development of 
computational models may benefit from the development of current research. Here we propose 
















rapidly-evolving research approaches recently in the AI field, with the overall aim of better-
predicting drug synergy. 
While DL methods show a great success on Euclidean data, those non-Euclidean data, like 
chemical data represented as graphs, need to be effectively analyzed. Inspired by the ideas of 
Convolutional Neural Network (CNN) and Recurrent Neural Network (RNN) from DL 
methods, AI researchers have developed the architecture of GCN to analyze and solve the 
complexity of graph data (Figure 2A). GCN has already had great applications on medical 
predicting tasks since it aims to learn a representation of each node with respect to its neighbors. 
Torng and Altman also use GCN to predict drug-target interactions9. We believe that this 
approach may have a significant effect when predicting synergy scores of drug combinations 
if we can adequately define the "graph" for drug combinations.  
    Besides, before introducing the RL approach, we would like to introduce the basic idea of 
the Markov decision process (MDP). Different from Hidden Markov Model (HMM), in which 
the next state is only affected by the current state, MDP takes the actions of the agent into 
consideration (i.e., the next state is affected by the current state and the current action). An 
MDP consists of 4 parts: States (S), Actions (A), Transition Probability (฀฀฀), and Reward 
function (R). The transition probability means the probability distribution from the current state 
to the next state, and the reward function means the reward that the agent will gain if it takes 
action from the current state (i.e., ฀ ×฀ → ฀). The solution of the Markov decision process 
is a policy (π) that describes the series of best actions that the agent takes in each state, as well 
as the real values (V) for it. 
    Under the basic definitions of the Markov decision process, if the transition probabilities and 
rewards are unknown, then the Markov decision process problem will become a Reinforcement 
Learning problem. Reinforcement Learning is an area of machine learning and it describes an 
















In figure 2B, we present the flowchart of the Deep Reinforcement Learning (DRL) algorithm, 
which is derived from RL and add the idea of Deep Neural Network when estimating the Q-
value. Then, the agent will select the next action by maximizing the Q-value of each action. In 
recently published papers, Popova et al. have used the DRL algorithms on drug discovery 10. If 
we properly define the state space and the actions, DRL may also be applied to predict drug 
synergy. Also, other reinforcement learning approaches, like State-action-reward-state-action 
(SARSA) or Q-learning (Figure 2C), may provide contributions to this field in the future as 
well. 
To sum up, this paper summarizes current machine learning models for predicting synergy 
scores of drug combinations. How to improve the predictive performance remains to be 
explored because of 1) insufficient data 2) non-deep biological understanding 3) a missing 
standard metric or benchmark. Although these limitations may not be solved in a short time, 
we believe that the performance could be enhanced using current datasets through proper novel 
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Figure 1 Schematic illustrations of the machine learning approach for predicting drug 
synergy. (A) The machine learning model for predicting drug synergy by combining the 
simulated genomic profiles of cancer cell lines and the monotherapy data, which ranked first 
in the drug combination prediction DREAM challenge. (B) the DeepSynergy model using drug 
and cell line information to predict synergy. (C) the SynGeNet model for predicting drug 
synergy by using the co-mutated genes and disease-associated gene expression signature. (D) 
the network-based model to predict drug synergy. 
Figure 2 Schematic illustrations of the Graph Convolutional Network and Reinforcement 
Learning approach. (A) The flowcharts of the Graph Convolutional Network, where the 
convolution operation is done on paths that connects the atoms of the chemicals. (B) the
overview of the Deep Reinforcement Learning approach. (C) the resulting path generated by 
two classic Reinforcement Learning algorithms. 
 
Supplemental Materials 
(Supplementary Text) 
Supplementary Text 
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
A
D
C
B
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
A
B C
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
